000269039 001__ 269039
000269039 005__ 20240808164524.0
000269039 0247_ $$2doi$$a10.1016/j.neuropharm.2024.109941
000269039 0247_ $$2ISSN$$a0028-3908
000269039 0247_ $$2ISSN$$a1873-7064
000269039 0247_ $$2altmetric$$aaltmetric:161536344
000269039 0247_ $$2pmid$$apmid:38565393
000269039 037__ $$aDZNE-2024-00470
000269039 082__ $$a610
000269039 1001_ $$0P:(DE-2719)2811671$$aMcManus, Róisín M.$$b0$$eFirst author
000269039 245__ $$aNLRP3 inflammasome signalling in Alzheimer's disease
000269039 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2024
000269039 3367_ $$2DRIVER$$aarticle
000269039 3367_ $$2DataCite$$aOutput Types/Journal article
000269039 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1718026977_5324$$xReview Article
000269039 3367_ $$2BibTeX$$aARTICLE
000269039 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000269039 3367_ $$00$$2EndNote$$aJournal Article
000269039 520__ $$aEvery year, 10 million people develop dementia, the most common of which is Alzheimer's disease (AD). To date, there is no way to prevent cognitive decline and therapies are limited. This review provides a neuroimmunological perspective on the progression of AD, and discusses the immune-targeted therapies that are in preclinical and clinical trials that may impact the development of this disease. Specifically, we look to the role of the NLRP3 inflammasome, its triggers in the brain and how its activation can contribute to the progression of dementia. We summarise the range of inhibitors targeting the NLRP3 inflammasome and its downstream pathways that are under investigation, and discuss future therapeutic perspectives for this devastating condition.
000269039 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000269039 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000269039 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000269039 650_2 $$2MeSH$$aAnimals
000269039 650_2 $$2MeSH$$aHumans
000269039 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000269039 650_2 $$2MeSH$$aAlzheimer Disease: immunology
000269039 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000269039 650_2 $$2MeSH$$aBrain: metabolism
000269039 650_2 $$2MeSH$$aBrain: immunology
000269039 650_2 $$2MeSH$$aInflammasomes: metabolism
000269039 650_2 $$2MeSH$$aNLR Family, Pyrin Domain-Containing 3 Protein: metabolism
000269039 650_2 $$2MeSH$$aNLR Family, Pyrin Domain-Containing 3 Protein: antagonists & inhibitors
000269039 650_2 $$2MeSH$$aSignal Transduction: physiology
000269039 650_2 $$2MeSH$$aSignal Transduction: drug effects
000269039 650_7 $$2Other$$aAlzheimer's disease
000269039 650_7 $$2Other$$aImmune-targeted therapies
000269039 650_7 $$2Other$$aMicroglia
000269039 650_7 $$2Other$$aNLRP3 inflammasome
000269039 650_7 $$2Other$$aNeuroimmunology
000269039 650_7 $$2Other$$aPreclinical models
000269039 650_7 $$2NLM Chemicals$$aInflammasomes
000269039 650_7 $$2NLM Chemicals$$aNLR Family, Pyrin Domain-Containing 3 Protein
000269039 650_7 $$2NLM Chemicals$$aNLRP3 protein, human
000269039 7001_ $$0P:(DE-2719)2000062$$aLatz, Eicke$$b1$$udzne
000269039 773__ $$0PERI:(DE-600)1500655-4$$a10.1016/j.neuropharm.2024.109941$$gVol. 252, p. 109941 -$$p109941$$tNeuropharmacology$$v252$$x0028-3908$$y2024
000269039 8564_ $$uhttps://pub.dzne.de/record/269039/files/DZNE-2024-00470.pdf$$yOpenAccess
000269039 8564_ $$uhttps://pub.dzne.de/record/269039/files/DZNE-2024-00470.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000269039 909CO $$ooai:pub.dzne.de:269039$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000269039 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811671$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000269039 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2000062$$aExternal Institute$$b1$$kExtern
000269039 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000269039 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000269039 9141_ $$y2024
000269039 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000269039 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000269039 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000269039 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROPHARMACOLOGY : 2022$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000269039 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000269039 9201_ $$0I:(DE-2719)1013024$$kAG Latz ; AG Latz$$lInnate Immunity in Neurodegeneration$$x0
000269039 9201_ $$0I:(DE-2719)1013042$$kAG McManus$$lTranslational Neuroimmunology$$x1
000269039 980__ $$ajournal
000269039 980__ $$aVDB
000269039 980__ $$aI:(DE-2719)1013024
000269039 980__ $$aI:(DE-2719)1013042
000269039 980__ $$aUNRESTRICTED
000269039 9801_ $$aFullTexts